Utah Department of
Health & Human Services
Center for Medical Cannabis

Utah Cannabis Research Review Board

Tuesday, October 11, 2022
9:00-11:00 am

Utah Department of Health and Human Services

This meeting was held virtually.

This meeting was recorded. An audio copy of this recording can be found on the Utah Public Notice Website (https://www.utah.gov/pmn/) and on the Cannabis Research Review Board YouTube https://www.youtube.com/channel/UCJW8IN0h7wQ3ojY33gZC8cw

Visit the Board's website for more information on past meeting minutes and agendas (https://medicalcannabis.utah.gov/resources/cannabinoid-product-board/)

Attendees

Board Members Attending: Katherine Carlson, Matt McIff, Misty Smith, Brian Zehnder, Mike Moss, Jennifer Norris

DHHS and AAG Staff Attending: Rich Oborn, Rachel Devine, Sarah Ponce, Lauren Heath, Danielle Conlon, Jeremiah Sniffin

Meeting Minutes

1. Welcome – Dr. Carlson

Dr. Carlson acknowledged that there was a quorum so the meeting could proceed with actions from the board.

2. Approval of September 2022 Minutes – Dr. Carlson

Dr. Smith moved to approve the minutes from the CRRB meeting in September. Dr. McIff seconded the motion. The minutes passed unanimously.

3. Annual Report - Dr. Carlson

You can expect approval of the annual report by 11/1/22.

4. Highway Safety and Cannabis Use Update - Mike Moss

Dr. Moss presented slides about the effects of driving on medical cannabis. He expressed that it can be challenging for regulators to impose an allowable limit for THC levels. Additionally, intoxication from the combination of THC and alcohol can worsen the level of impairment.

5. General Instructions for the Use of Medical Cannabis - Rich Oborn
    a. Guidance Document Pages 8 - 16

Mr. Oborn presented to the Board the original Guidance Document, which included dosing guidelines for people who are beginning to use cannabis, or increasing their dosage of cannabis. Dr. Carlson suggested that we could reproduce the dosing guidelines so that they aren't buried in a lengthy document, but instead make them more accessible to pharmacies and the public.

Board members suggested that the market should make more of an effort to produce smaller doses of product, and that if the CRRB wants to review quality research, we need more consistent dosing for patients.

6. Public Health Outreach Efforts - Danielle Conlon

Ms. Conlon will soon be working with a QMP Consultant, who will help produce communications for DHHS with QMPs. Once that contract is finalized and signed, the Center for Medical Cannabis will provide information about who the QMP consultant is and they will start working on outreach with DHHS.

Ms. Conlon is also putting together a social media marketing campaign using public health guidelines on the Center for Medical Cannabis website. The campaign will be posted on DHHS general social media channels, and shareable with program partners.

7. Center for Medical Cannabis updates – Rich Oborn

The CMC is close to finalizing a public notice it plans to send to medical cannabis card holders and stakeholders regarding synthetic and derivative cannabinoids. The CMC is holding a medical cannabis market analysis input meeting on Tuesday, Oct. 25, 4-5pm. At the meeting, the CMC will receive input from the public and the industry regarding the quality, supply, and variety of medical cannabis products manufactured and sold to patients in Utah.

The CMC is working with stakeholders on drafting administrative rules related to the delivery of medical cannabis to health care facilities.

The CMC expects state lawmakers to propose multiple amendments to the Utah Medical Cannabis Act (UCA 26-61a) during the 2023 General Legislative Session.

The 15th medical cannabis pharmacy is scheduled to open later this month in Price, UT.

8. Public Comment

Christine Stenquist represents TRUCE, a patient advocacy group. Ms. Stenquist thanked Dr. Moss for his presentation on traffic safety and the use of cannabis. Ms. Stenquist said it will take a long time to standardize product ingredients and dosing. Products that contain synthetic ingredients and derivatives like Delta 6 products need to be regulated to protect the health and safety of patients.

Zac Newel King is a patient. Mr. King wants the medical cannabis program in Utah to focus on providing more access to organic medicine rather than synthetic ingredients. Mr. King likes that the CRRB is pushing for standardization of dosing and ingredients. He hopes that the cannabis market can push towards lowering costs so patients can afford their daily medication and dosage.

Valerie Ahanonu is Vice Chair of Truce and currently works at Terra Health. Ms. Ahanonu stated that regarding dosing, the real reason DEA and FDA are is focused on this and giving us the option to have medical cannabis is because of the safety

profile of THC. Ms Ahanonu wants the CRRB to further research cannabis products and dosing so that patients can have access to specialized care.

Jake Garnlate is a patient. Mr. Garnlate had an issue with a goal he heard earlier in the meeting to reduce dosage over time, as well as the idea that we should standardize cannabis. He felt cannabis is different from man-made medicine and pharmaceuticals.

Mark Viner, MD Psychiatry. Utah licensed physician and practicing in Nevada. Dr. Viner expressed concern about the derivatives and synthetic ingredients, and he suggested that regulators need to come up with a better classification of the derivatives. Dr. Viner would classify as First generation (K2/Spice like) and Second generation (hemp derived THC products) synthetic cannabinoid. For synthetic cannabinoids, he thought they should be traditional and then hemp derived. Regarding dosing, Dr. Viner stated that the science around dosing that the CRRB was reviewing was based around studies where they used an intravenous method. He suggested to approach the dosing with route of administration and dose for each route (IV, Oral, Transdermal, and so on) and then for each category of disorder Seizures, Pain and so on.

Amy King is an advisor to TRUCE and a member of ASTM, one of the largest voluntary standards developing organizations in the world. Ms. King has been working on their team to develop standards for cannabis products. They have a subcommittee for government relations, and she would love to see the Board, DHHS, and UDAF join and attend these meetings. Ms. King asked if the bulletin about the synthetic and derivative cannabis ingredients will indicate the law requires testing to ensure "the product is safe for human consumption" ALONG with accurate labeling - and that no Utah department or agency has ensured the safety of these "analogs"?

Kristen Larsen is a patient in Utah. Ms. Larson commented that concerning the safety and purity of products, she bought cannabis flower in October and it was harvested in May. She stated that this amount of time can diminish the

effectiveness of the product. Can patients get to a point in the future of growing the plant in their own backyard?

9. Close

Dr. McIff motioned to conclude the meeting, and Dr. Moss seconded. The meeting was adjourned.

Notes: